NeuroPace, Inc. (NPCE)

Market Cap	102.40M
Revenue (ttm)	45.52M
Net Income (ttm)	-47.08M
Shares Out	25.10M
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,006
Open	3.89
Previous Close	3.93
Day's Range	3.89 - 4.08
52-Week Range	1.22 - 9.30
Beta	n/a
Analysts	Buy
Price Target	7.04 (+72.55%)
Earnings Date	May 11, 2023

About NPCE

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorpor...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 22, 2021
• Employees: 174
• Stock Exchange: NASDAQ
• Ticker Symbol: NPCE

Financial Performance

In 2022, NeuroPace's revenue was $45.52 million, an increase of 0.75% compared to the previous year's $45.18 million. Losses were -$47.08 million, 30.5% more than in 2021.

Analyst Forecast

According to 11 analysts, the average rating for NPCE stock is "Buy." The 12-month stock price forecast is $7.04, which is an increase of 72.55% from the latest price.

Price Target

$7.04

(72.55% upside)

Analyst Consensus: Buy